-
Mashup Score: 32Gemtuzumab ozogamicin plus 7 + 3 induction therapy in patients with intermediate-risk ND AML - 1 day(s) ago
Here, we summarize a real-world retrospective analysis by Awada et al. investigating whether the addition of gemtuzumab ozogamicin to intensive 7 + 3 induction therapy is beneficial in patients with intermediate-risk ND AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therapy in patients with AML?
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
On April 22, 2024, the U.S. FDA granted Breakthrough Therapy Designation to ziftomenib, a novel therapy that targets the menin-KMT2A/MLL protein-protein interaction, for the treatment of NPM1-mutated R/R AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨 NEWS 🚨 @US_FDA grants Breakthrough Therapy Designation for ziftomenib, a novel therapy that targets the menin-KMT2A/MLL protein-protein interaction, for the treatment of NPM1-mutated AML. Read more here 👉 https://t.co/B7yl3hgANv #AMLsm #leusm #leukemia #MedicalEducation https://t.co/uIlePVyzDZ
-
-
Mashup Score: 5
Here, we summarize a validation of the Oncomine Myeloid Assay GX v2 in myeloid malignancies published by Zbieranski and Insuasti-Beltran.1 in The Journal of Molecular Diagnostics.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Annamycin granted Orphan Drug Designation by the EMA - 4 day(s) ago
On April 18, 2024, the European Medicines Agency granted Orphan Drug Designation to annamycin, a next-generation anthracycline, for the treatment of patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1BVX001 granted Orphan Drug Designation by the U.S. FDA - 8 day(s) ago
On April 17, 2024, the U.S. Food and Drug Administration granted Orphan Drug Designation to BVX001, a novel twin CD33/CD7 targeting bispecific antibody-drug conjugate, for the treatment of patients with acute myeloid leukemia.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Annamycin granted Orphan Drug Designation by the EMA - 8 day(s) ago
On April 18, 2024, the European Medicines Agency granted Orphan Drug Designation to annamycin, a next-generation anthracycline, for the treatment of patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Here, we summarize a multicenter retrospective study evaluating the efficacy and safety of ivosidenib in patients with IDH1-mutated R/R AML post-allo-HSCT.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Oral decitabine and cedazuridine + venetoclax for the treatment of older patients with newly diagnosed AML - 15 day(s) ago
Here, we summarize a phase II study investigating the efficacy and safety of the oral decitabine and cedazuridine + venetoclax for the treatment of patients aged ≥60 years with newly diagnosed AML or with relapsed/refractory AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax - 18 day(s) ago
Following to the previous information on March 11th, 2024, we are excited to share our latest development status. We are pleased to announce the proto
Source: www.businesswire.comCategories: General Medicine News, Onc News and JournalsTweet
Is there a survival benefit from the addition of gemtuzumab ozogamicin to 7 + 3 induction therapy in patients with ND AML and intermediate cytogenetics? Read more here: https://t.co/wJFa2I0Hd8 #AMLsm #leusm #leukemia #MedicalEducation https://t.co/h8uZNNdWED